Abstract
Adhesion molecules participate in many stages of immune response; they regulate leukocyte circulation, lymphoid cell homing to tissues and inflammatory sites, migration across endothelial cells and T-cell stimulation. During Tcell immune response, adhesion molecules form a specialized junction between T-cell and the antigen presenting cell. Thus, many researchers have focused their attention on targeting adhesion molecules for developing therapeutic agents. Most of these efforts are intended to develop drugs for autoimmune and inflammatory diseases. Therapeutic agents like efalizumab and alefacept have been approved by the FDA for the treatment of inflammatory autoimmune diseases. This review focuses on some of the basic aspects and importance of adhesion molecules, recent understanding of the structure of adhesion molecules, and the targeted therapeutic agents.
Keywords: Alefacept, CD2, cell adhesion molecules, efalizumab, ICAM-1, LFA-1, LFA-3
Current Pharmaceutical Design
Title: Targeting T-Cell Adhesion Molecules for Drug Design
Volume: 12 Issue: 22
Author(s): Seetharama D.S. Jois, Liu Jining and Latha M. Nagarajarao
Affiliation:
Keywords: Alefacept, CD2, cell adhesion molecules, efalizumab, ICAM-1, LFA-1, LFA-3
Abstract: Adhesion molecules participate in many stages of immune response; they regulate leukocyte circulation, lymphoid cell homing to tissues and inflammatory sites, migration across endothelial cells and T-cell stimulation. During Tcell immune response, adhesion molecules form a specialized junction between T-cell and the antigen presenting cell. Thus, many researchers have focused their attention on targeting adhesion molecules for developing therapeutic agents. Most of these efforts are intended to develop drugs for autoimmune and inflammatory diseases. Therapeutic agents like efalizumab and alefacept have been approved by the FDA for the treatment of inflammatory autoimmune diseases. This review focuses on some of the basic aspects and importance of adhesion molecules, recent understanding of the structure of adhesion molecules, and the targeted therapeutic agents.
Export Options
About this article
Cite this article as:
Jois D.S. Seetharama, Jining Liu and Nagarajarao M. Latha, Targeting T-Cell Adhesion Molecules for Drug Design, Current Pharmaceutical Design 2006; 12 (22) . https://dx.doi.org/10.2174/138161206777947696
DOI https://dx.doi.org/10.2174/138161206777947696 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy for Immunologic Tolerance: Using Bone Marrow-Derived Cells to Treat Autoimmunity and Hemophilia
Current Stem Cell Research & Therapy Chemokines as Drug Targets in Type 1 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets PCR/SSCP Detects Reliably and Efficiently DNA Sequence Variations in Large Scale Screening Projects
Combinatorial Chemistry & High Throughput Screening Chitosan Nanoparticles: A Therapeutic Carrier for Delivery of DNA, siRNA and CpG-ODNs
Nanoscience & Nanotechnology-Asia Transcription Factors in Autoimmune Diseases
Current Pharmaceutical Design Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Novel Molecular Targets for Systemic Lupus Erythematosus and Other Immune-Complex and T-Cell Mediated Autoimmune Diseases - Update
Medicinal Chemistry Reviews - Online (Discontinued) Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Animal Models to Investigate Pathomechanisms and Evaluate Novel Treatments for Autoimmune Bullous Dermatoses
Current Pharmaceutical Design Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology Targeting Interleukin-1β for Pain
CNS & Neurological Disorders - Drug Targets Selenium and Autoimmune Diseases: A Review Article
Current Rheumatology Reviews Use of Synbiotics for Ulcerative Colitis Treatment
Current Clinical Pharmacology Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging Vitiligo and Allergic Complications from Orthopaedic Joint Implants: The Role of Benzoyl Peroxide
Recent Patents on Inflammation & Allergy Drug Discovery Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies NF-κB-IKKβ Pathway as a Target for Drug Development: Realities, Challenges and Perspectives
Current Drug Targets Pharmacogenomics of Methotrexate: Current Status and Future Outlook
Current Drug Metabolism Vitiligo in Children: A Birds Eye View
Current Pediatric Reviews Human Use of Leucoselect® Phytosome® with Special Reference to Inflammatory- Allergic Pathologies in Frail Elderly Patients
Current Pharmaceutical Design